BofA raises target for Johnson & Johnson stock from USD 263 to USD 278

Published on 10/02/2026 at 17:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 6.60 percent to USD 25.31 billion. Johnson & Johnson stock costs EUR 227.88 on October 2, 2026 versus EUR 230.83.

Soft watercolor painting of a city skyline across a calm misty river, a riverside park path in the foreground with a bench and lamp post under mature green trees, pastel blue sky, muted terracotta building facades reflected in the still water — Johnson stammt aus New Brunswick, US4781601046 Aquarell zeigt Skyline mit Fluss und Park, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 227.88 at Lang & Schwarz on October 2, 2026 at 5:01 p.m. CEST, down 1.28 percent from the EUR 230.83 prior close. On September 29, 2026, BofA raised its price target from USD 263.00 to USD 278.00 while keeping a Neutral rating, according to Yahoo Finance.

Icotyde outlook lifts BofA target

BofA's revised view centers on Icotyde, Johnson & Johnson's oral psoriasis treatment. The bank raised its peak-sales forecast for the drug to USD 4.5 billion from USD 2.4 billion, while its physician survey supported an 18.00 percent share of new advanced-treatment starts, as reported by Yahoo Finance on October 1, 2026.

The upgrade is measured rather than aggressive. BofA expects third-quarter 2026 sales of USD 25.5 billion but projects earnings per share of USD 2.53, below the USD 2.87 consensus, partly because of research costs tied to recent deals.

Quarterly growth meets valuation pressure

Johnson & Johnson reported USD 25.31 billion of revenue in the second quarter of 2026, up 6.60 percent from the year-earlier quarter, while adjusted earnings per share reached USD 2.90 versus USD 2.84 consensus, according to MarketBeat on September 29, 2026.

The company also reaffirmed fiscal 2026 adjusted earnings-per-share guidance of USD 11.60 to USD 11.75. That earnings base matters because the latest market capitalization was USD 619.4 billion on October 2, 2026, while the 52-week range stood at USD 182.94 to USD 281.07.

October earnings set the next test

JPMorgan raised its target from USD 270.00 to USD 285.00 on September 29, 2026 and retained a Neutral rating ahead of the earnings report, according to Markets Insider. The firm described the valuation as reflecting much of the favorable fundamental setup.

Johnson & Johnson is expected to announce fiscal third-quarter 2026 results before the market opens on October 13, 2026, with analysts looking for diluted earnings per share of USD 2.96, according to Yahoo Finance.

Stock trades below its prior close

At EUR 227.88, Johnson & Johnson stock was EUR 2.95 below its Lang & Schwarz prior close of EUR 230.83 on October 2, 2026, leaving the euro quote below the USD 278.00 and USD 285.00 analyst targets on separate currency bases. The company has a healthcare portfolio spanning Innovative Medicine and MedTech.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.